{
  "disease_name": "Glycogen storage disease due to glucose-6-phosphatase deficiency",
  "orpha_code": "364",
  "drugs": [
    {
      "name": "Diazoxide choline",
      "substance_url": "/en/drug/substance/403944?name=364&mode=orpha&region=&status=all",
      "substance_id": "403944",
      "regulatory_url": "/en/drug/regulatory/692363?name=364&mode=orpha&region=",
      "regulatory_id": "692363",
      "orpha_substance_code": "ORPHA:364",
      "details": [
        "Diazoxide choline(Medicinal product                        - 13/12/2024)Disease(s) concernedORPHA:364 Glycogen storage disease due to glucose-6-phosphatase deficiency",
        "Diazoxide choline(Medicinal product                        - 13/12/2024)",
        "(Medicinal product                        - 13/12/2024)",
        "Disease(s) concernedORPHA:364 Glycogen storage disease due to glucose-6-phosphatase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/403944?name=364&mode=orpha&region=&status=all",
          "text": "Diazoxide choline",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/364",
          "text": "ORPHA:364 Glycogen storage disease due to glucose-6-phosphatase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/692363?name=364&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "due to glucose-6-phosphatase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Diazoxide choline",
      "substance_url": "/en/drug/substance/403944?name=364&mode=orpha&region=&status=all",
      "substance_id": "403944",
      "regulatory_url": "/en/drug/regulatory/707968?name=364&mode=orpha&region=",
      "regulatory_id": "707968",
      "orpha_substance_code": "ORPHA:364",
      "details": [
        "Diazoxide choline(Medicinal product                        - 26/05/2021)Disease(s) concernedORPHA:364 Glycogen storage disease due to glucose-6-phosphatase deficiency",
        "Diazoxide choline(Medicinal product                        - 26/05/2021)",
        "(Medicinal product                        - 26/05/2021)",
        "Disease(s) concernedORPHA:364 Glycogen storage disease due to glucose-6-phosphatase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/403944?name=364&mode=orpha&region=&status=all",
          "text": "Diazoxide choline",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/364",
          "text": "ORPHA:364 Glycogen storage disease due to glucose-6-phosphatase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/707968?name=364&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "due to glucose-6-phosphatase deficiency\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "mRNA encoding human glucose-6-phosphatase variant S298C",
      "substance_url": "/en/drug/substance/628240?name=364&mode=orpha&region=&status=all",
      "substance_id": "628240",
      "regulatory_url": "/en/drug/regulatory/628244?name=364&mode=orpha&region=",
      "regulatory_id": "628244",
      "orpha_substance_code": "ORPHA:79258",
      "details": [
        "mRNA encoding human glucose-6-phosphatase variant S298C(Medicinal product                        - 14/01/2022)Disease(s) concernedORPHA:79258 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia",
        "mRNA encoding human glucose-6-phosphatase variant S298C(Medicinal product                        - 14/01/2022)",
        "(Medicinal product                        - 14/01/2022)",
        "Disease(s) concernedORPHA:79258 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/628240?name=364&mode=orpha&region=&status=all",
          "text": "mRNA encoding human glucose-6-phosphatase variant S298C",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/79258",
          "text": "ORPHA:79258 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/628244?name=364&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "due to glucose-6-phosphatase deficiency type Ia\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene",
      "substance_url": "/en/drug/substance/485069?name=364&mode=orpha&region=&status=all",
      "substance_id": "485069",
      "regulatory_url": "/en/drug/regulatory/485070?name=364&mode=orpha&region=",
      "regulatory_id": "485070",
      "orpha_substance_code": "ORPHA:79258",
      "details": [
        "adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene(Medicinal product                        - 18/11/2016)Disease(s) concernedORPHA:79258 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia",
        "adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene(Medicinal product                        - 18/11/2016)",
        "(Medicinal product                        - 18/11/2016)",
        "Disease(s) concernedORPHA:79258 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/485069?name=364&mode=orpha&region=&status=all",
          "text": "adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/79258",
          "text": "ORPHA:79258 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/485070?name=364&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "due to glucose-6-phosphatase deficiency type Ia\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Lipid nanoparticles containing prime editing components (mRNA, pegRNA and ngRNA) capable of editing genetic mutations in the SLC37A4 gene",
      "substance_url": "/en/drug/substance/689527?name=364&mode=orpha&region=&status=all",
      "substance_id": "689527",
      "regulatory_url": "/en/drug/regulatory/689729?name=364&mode=orpha&region=",
      "regulatory_id": "689729",
      "orpha_substance_code": "ORPHA:79259",
      "details": [
        "Lipid nanoparticles containing prime editing components (mRNA, pegRNA and ngRNA) capable of editing genetic mutations in the SLC37A4 gene(Medicinal product                        - 04/10/2024)Disease(s) concernedORPHA:79259 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib",
        "Lipid nanoparticles containing prime editing components (mRNA, pegRNA and ngRNA) capable of editing genetic mutations in the SLC37A4 gene(Medicinal product                        - 04/10/2024)",
        "(Medicinal product                        - 04/10/2024)",
        "Disease(s) concernedORPHA:79259 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/689527?name=364&mode=orpha&region=&status=all",
          "text": "Lipid nanoparticles containing prime editing components (mRNA, pegRNA and ngRNA) capable of editing genetic mutations in the SLC37A4 gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/79259",
          "text": "ORPHA:79259 Glycogen storage disease due to glucose-6-phosphatase deficiency type Ib",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/689729?name=364&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "due to glucose-6-phosphatase deficiency type Ib\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Burixafor",
      "substance_url": "/en/drug/substance/689505?name=364&mode=orpha&region=&status=all",
      "substance_id": "689505",
      "regulatory_url": "/en/drug/regulatory/689915?name=364&mode=orpha&region=",
      "regulatory_id": "689915",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Burixafor(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Burixafor(Medicinal product                        - 22/10/2024)",
        "(Medicinal product                        - 22/10/2024)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/689505?name=364&mode=orpha&region=&status=all",
          "text": "Burixafor",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/689915?name=364&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Treosulfan",
      "substance_url": "/en/drug/substance/90799?name=364&mode=orpha&region=&status=all",
      "substance_id": "90799",
      "regulatory_url": "/en/drug/regulatory/136690?name=364&mode=orpha&region=",
      "regulatory_id": "136690",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Treosulfan(Medicinal product                        - 08/04/2015)Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Treosulfan(Medicinal product                        - 08/04/2015)",
        "(Medicinal product                        - 08/04/2015)",
        "Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/90799?name=364&mode=orpha&region=&status=all",
          "text": "Treosulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/213500",
          "text": "ORPHA:213500 Rare ovarian cancer",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/136690?name=364&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "busulfan",
      "substance_url": "/en/drug/substance/46335?name=364&mode=orpha&region=&status=all",
      "substance_id": "46335",
      "regulatory_url": "/en/drug/regulatory/131973?name=364&mode=orpha&region=",
      "regulatory_id": "131973",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "busulfan(Medicinal product                        - 21/04/1994)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "busulfan(Medicinal product                        - 21/04/1994)",
        "(Medicinal product                        - 21/04/1994)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/46335?name=364&mode=orpha&region=&status=all",
          "text": "busulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131973?name=364&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    }
  ],
  "processing_timestamp": "2025-07-07T06:01:35.692055",
  "run_number": 1,
  "total_drugs_found": 8,
  "search_url": "https://www.orpha.net/en/drug?diseaseName=Glycogen+storage+disease+due+to+glucose-6-phosphatase+deficiency&orphaCode=364&name=364&region=&mode=orpha&status=all",
  "search_params": {
    "diseaseName": "Glycogen storage disease due to glucose-6-phosphatase deficiency",
    "orphaCode": "364",
    "name": "364",
    "region": "",
    "mode": "orpha",
    "status": "all"
  }
}